Adjuvant Rx yields minor benefit in less aggressive colon cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 10
Volume 18
Issue 10

Stage II colon cancer patients who are negative for microsatellite instability and lymphocytic infiltrate should not undergo adjuvant chemotherapy, according to surgeons at Oregon Health and Science University and Legacy Health System, both in Portland.

Stage II colon cancer patients who are negative for microsatellite instability and lymphocytic infiltrate should not undergo adjuvant chemotherapy, according to surgeons at Oregon Health and Science University and Legacy Health System, both in Portland.

These patients tend to have a less favorable prognosis and may be candidates for more aggressive adjunctive therapy, wrote Sandeep Kumar, MD, and colleagues (Arch Surg 144:835-840, 2009).

The authors prospectively evaluated 167 colon cancer patients for MSI and LI status and then retrospectively evaluated their chemotherapy regimens. Disease-free survival (DFS) with and without chemotherapy according to combined MSI and LI status was the main outcome.

In the 140 patients for whom data were available, the five-year DFS was 50% for patients who underwent chemotherapy vs 76% for those who did not (P = .02). In the group negative for MSI and LI, five-year DFS was 29% for those undergoing chemotherapy and 91% for those who did not (P = .001).

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Related Content